InvestorsHub Logo
Followers 97
Posts 11249
Boards Moderated 7
Alias Born 06/06/2017

Re: None

Friday, 09/18/2020 2:40:43 PM

Friday, September 18, 2020 2:40:43 PM

Post# of 13599
3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline
12:35 pm ET September 18, 2020 (Benzinga) Print
Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas.

The Moderna Analysts: Chardan analyst Geulah Livshits has a Buy rating on Moderna with a $95 price target.

SVB Leerink analyst Mani Foroohar maintained an Underpeform rating and $41 price target.

Needham analyst Alan Carr reiterated a Buy rating and $94 price target.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News